Last updated: July 17, 2026
Gilead Sciences v. Aurobindo Pharma (1:16-cv-03722): Litigation Summary, Patent Issues, and Generic Entry Risk
Executive summary:
In Gilead Sciences, Inc. v. Aurobindo Pharma Ltd. (E.D.N.Y.) No. 1:16-cv-03722, the case centers on patent challenges tied to Aurobindo’s FDA ANDA pathway for a Gilead small-molecule drug. The litigation posture reflects a typical Hatch-Waxman dispute: Gilead asserts infringement of listed patents covering the claimed drug product, while Aurobindo defends via invalidity/non-infringement arguments and often argues non-coverage or Section 505(j) carve-outs. Without the docket’s asserted patent list and the parties’ claim-construction record, a complete infringement/invalidity mapping and a precise exclusivity-to-entry risk calculation cannot be produced from the case caption alone.
What can be stated from the case identification:
- Parties: Gilead Sciences, Inc. (plaintiff) v. Aurobindo Pharma Ltd. (defendant)
- Court / docket: E.D.N.Y., 1:16-cv-03722
- Program type implied by typical Gilead v. ANDA disputes: Hatch-Waxman ANDA patent litigation with Orange Book-listed patents.
What cannot be stated from the caption alone (required for a high-precision litigation analysis):
- The exact asserted patents (numbers and expiration dates)
- Whether the dispute resolved via claim dismissal, summary judgment, stipulation, settlement, or consent judgment
- Whether there were Paragraph IV certifications tied to specific patents
- The trigger date for any 30-month stay lift or settlement effective date
- The specific product strength/dosage form (tablet, film-coated, etc.) implicated by the ANDA
- The procedural milestones (Markman order, amended complaints, trial dates, dispositive motions outcomes)
- The final injunction scope or any authorized generic or launch design-around language.
Because your request is for a litigation summary and analysis, the above missing elements are determinative. A complete, accurate, business-usable summary requires the asserted patent set and case outcome details.
What patents are at issue in Gilead v. Aurobindo Pharma (1:16-cv-03722)?
Featured snippet answer: The case caption alone does not provide the asserted patent numbers, the Orange Book listing identifiers, or the specific FDA ANDA reference product.
Which Orange Book patents typically drive Gilead v. ANDA cases?
In Gilead small-molecule portfolios, asserted patents in ANDA litigation usually fall into one or more of these buckets:
- Composition of matter (active ingredient or crystalline form)
- Formulation patents (excipients, film coating, particle size, solid-state properties)
- Method-of-use patents (dosing regimens, treatment indications)
- Manufacturing/process patents.
How to read the case if you only have the docket number
For 1:16-cv-03722, the actionable step for patent scope is to pull:
- the complaint (asserted patents and infringement theories)
- the claim chart basis (if included in filings)
- the contentions and any Markman order
- the final judgment/settlement document (if resolved).
No such patent identifiers are present in the prompt, so a precise mapping cannot be produced.
When does the 30-month stay or exclusivity end in Gilead v. Aurobindo (1:16-cv-03722)?
Featured snippet answer: The docket identification does not reveal the ANDA submission date, the Paragraph IV trigger, or the 30-month stay timeline.
What determines the stay timeline
In Hatch-Waxman:
- the Paragraph IV certification date and ANDA acceptance drive the initial stay window
- any timely court decisions can shorten the stay
- settlement agreements can modify practical launch timing via negotiated effective dates.
Without ANDA certification and procedural dates from the docket, an exclusivity-to-entry timeline would be speculative.
How strong is Gilead’s patent estate in the 1:16-cv-03722 dispute?
Featured snippet answer: Patent strength cannot be assessed without the asserted patent claims, their priority dates, and the litigated claim construction.
Litigation strength factors that require docket specifics
- claim construction outcomes for key limitations
- validity challenges (anticipation/obviousness) tied to specific prior art
- whether the court granted or denied summary judgment on non-infringement/invalidity
- whether the case ended with a consent judgment that implies perceived risk allocation.
No such details appear in the provided information.
What generic entry risks exist for Aurobindo if Gilead v. Aurobindo (1:16-cv-03722) settled or was dismissed?
Featured snippet answer: Entry risk depends on the final disposition and any settlement terms (launch date, design-around requirements, carve-outs, permitted stockpiling).
Common settlement outcomes in Gilead ANDA litigation
Typical provisions include:
- a “no-launch” commitment through an effective date
- stipulations on certain claims/patents
- limits on label changes, strength coverage, or manufacturing process.
A business-usable risk assessment requires the settlement or judgment terms, which are not included in the prompt.
What does the case say about formulations or dosing covered by patents?
Featured snippet answer: The prompt does not identify the drug or the claimed formulation/dosing limitations, so no formulation scope can be derived.
Formulation and dosing points that are litigated in Gilead cases
Where asserted, courts typically evaluate:
- active ingredient form (salt/polymorph)
- granulation method, particle size, or solid-state properties
- excipient function impacting dissolution/bioavailability
- dosing regimen limitations in method-of-use claims.
No drug-specific claim facts are available here.
Is Aurobindo’s ANDA launch blocked, delayed, or allowed in 1:16-cv-03722?
Featured snippet answer: The docket outcome (dismissal with or without prejudice, summary judgment for Gilead, or settlement with a launch date) is not supplied, so launch status cannot be stated accurately.
How to determine launch status from the docket
You would need:
- the final judgment entry date
- the settlement agreement effective date (if available)
- any “remaining patents” list after discontinuance.
These are not present in the prompt.
Which companies challenge the same Gilead product after Aurobindo in similar ANDA cases?
Featured snippet answer: The underlying product is not identified, so cross-defendant landscape cannot be determined.
Why the product identity is required
Gilead disputes are heavily product-specific. Competitor patterns in ANDA litigation differ by:
- the drug’s patent density
- the number of authorized generic filers
- the presence of multiple dosage strengths or combination regimens.
Without the product, competitor analysis would be unreliable.
Key Takeaways
- The docket number (1:16-cv-03722) and party names confirm an ANDA-style patent dispute but do not provide the asserted patents, outcome, or launch implications needed for a litigation-grade summary.
- A patent-level and timing-level analysis cannot be completed from the caption alone because the decisive inputs are the asserted patent list, case disposition, and settlement or judgment terms.
FAQs
-
What patents were asserted by Gilead in 1:16-cv-03722?
Not determinable from the prompt.
-
Was the case resolved by settlement or court judgment?
Not determinable from the prompt.
-
Did Aurobindo obtain a non-infringement or invalidity ruling?
Not determinable from the prompt.
-
What was the effective date of any agreed launch limitation?
Not determinable from the prompt.
-
Does the case affect other defendants’ Paragraph IV certifications for the same Gilead product?
Not determinable from the prompt.
References
- Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., No. 1:16-cv-03722 (E.D.N.Y.).
